Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 9

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Mar 7, 2026; 32(9): 114580
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.114580

Table 2 Multivariate Cox regression model for first clinical remission during follow-up, Canadian IBD Research Consortium cohort, Canada, 2018-2024

Characteristic	Unadjusted HR (95%CI)	Adjusted HR (95%CI)
Biosimilar at enrollment	1.06 (0.70-1.60)	1.49 (0.96-2.32)
Female sex	0.96 (0.67-1.38)	0.96 (0.66-1.40)
Age at IBD diagnosis	0.99 (0.98-1.00)	0.99 (0.98-1.01)
IBD duration at biologic start	1.00 (0.98-1.02)	0.98 (0.96-1.00)
UC disease	0.50 (0.34-0.75)	0.35 (0.22-0.55)
Moderate or high disease activity¹	0.51 (0.35-0.74)	0.36 (0.23-0.54)
Previous use of biologic²	1.10 (0.66-1.84)	1.67 (0.93-2.99)
Corticosteroid use³	0.80 (0.55-1.16)	1.00 (0.68-1.59)
Immunomodulator use⁴	1.40 (0.97-2.02)	1.44 (0.97-2.13)
One or more comorbidity⁵	1.02 (0.71-1.48)	1.41 (0.93-2.14)

¹In Crohn’s disease, either a Harvey-Bradshaw Index > 8 or a Crohn's Disease Activity Index > 220; in ulcerative colitis, a Partial Mayo Score ≥ 5.

²Anytime before enrollment.

³Current or past 12 months before enrollment.

⁴Methotrexate and azathioprine.

⁵Congestive heart failure, diabetes, hypertension, coronary artery disease, malignancies, renal failure.

CI: Confidence interval; HR: Hazard ratio; IBD: Inflammatory bowel disease; UC: Ulcerative colitis.

Citation: Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S. Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars. World J Gastroenterol 2026; 32(9): 114580
URL: https://www.wjgnet.com/1007-9327/full/v32/i9/114580.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i9.114580

Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S. Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars. World J Gastroenterol 2026; 32(9): 114580 [PMID: 41810446 DOI: 10.3748/wjg.v32.i9.114580]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.